Teen Vaccination Coverage
2011 National Immunization Survey (NIS) – Teen
Key Points
The 2011 NIS-Teen coverage data show that national vaccination rates in adolescents aged 13 through 17 years have continued to improve for tetanus-diphtheria-pertussis (Tdap) vaccine and for meningococcal conjugate vaccine (MCV4).
National Tdap coverage rates for teens 13 through 15 years old met the Healthy People 2020 objective of 80 percent for the first time.
For the third year in a row however, the increase in coverage for human papillomavirus (HPV) vaccine is half of the increases seen for Tdap and MCV4 vaccine coverage.
HPV vaccine coverage rates are lower for younger girls, which tells us that girls are not receiving the HPV vaccine series at the recommended ages of 11 or 12 years.
Geographic disparities were evident in HPV vaccination, with southeastern U.S. states having lower rates than elsewhere. These states also have higher rates of cervical cancer.
Parents, healthcare providers and immunization partners all have a role in preventing HPV-related cancers and disease in both girls and boys:
- Parents need to know their child's HPV vaccination status. If your daughter or son has not started the HPV series and is 11-12 years old, make an appointment to do so. If they are 13 through 18 years old and haven’t started or finished the HPV vaccine series, it’s not too late to make an appointment for your child to receive HPV vaccine.
- Healthcare professionals should make strong recommendations and vaccinate every boy and girl in their practice when the patients are 11 or 12 years old. Missed opportunities data show that if HPV vaccine was given every time a clinician gave a Tdap or MCV4 dose, HPV vaccine coverage would be over 80 percent.
- Immunization partners can make HPV vaccination a priority and help educate their community on the importance of getting HPV vaccine for both girls and boys at the recommended ages of 11 or 12 years to prevent HPV-related cancer and disease.
NIS-Teen Survey Data Collected in 2011
Tdap Vaccine
- Nationally, Tdap increased by 9 percentage points reaching about 78 percent (68.7% in 2010 v. 78.2% in 2011).
- Coverage for one dose of Tdap was lower for those living below poverty.
Meningococcal Conjugate Vaccine (MCV4)
- MCV4 increased by nearly 8 percentage points to about 71 percent (62.7% in 2010 v. 70.5% in 2011).
- Coverage for one dose of MCV4 was higher among Hispanics than whites.
HPV Vaccine
- For girls who received at least one dose of HPV vaccine, coverage increased by 4 percentage points to 53 percent (48.7% in 2010 v 53.0% in 2011).
- Receipt of three doses increased by 3 percentage points to 35 percent (32.0% in 2010 v. 34.8% in 2011).
- Of the girls who started the series, and had adequate time to complete the series before the NIS-Teen interview date, about 29 percent did not receive all three recommended doses.
- HPV vaccination rates were lower among younger girls compared to older girls.
- The receipt of three HPV doses among those who had adequate time to complete the series before the interview date was lower among blacks than whites.
- The receipt of one or three HPV doses among was lower among whites than Hispanics.
- Completion of the 3 dose HPV series among those who had adequate time to complete the series before the interview date was lower for those living below poverty.
- For boys who received at least one dose of HPV vaccine, coverage increased by 7 percentage points to about 8 percent (1.4% in 2010 v. 8.3% in 2011).
- Receipt of three doses is 1 percent.
- Of the boys who began the series and had adequate time to finish the series before the NIS-Teen interview date, 28 percent completed the series.
NIS-Teen Vaccination Coverage Data Tables
Images and logos on this website which are trademarked/copyrighted or used with permission of the trademark/copyright or logo holder are not in the public domain. These images and logos have been licensed for or used with permission in the materials provided on this website. The materials in the form presented on this website may be used without seeking further permission. Any other use of trademarked/copyrighted images or logos requires permission from the trademark/copyright holder...more
This graphic notice means that you are leaving an HHS Web site. For more information, please see the Exit Notification and Disclaimer policy.
Contact Us:
- Centers for Disease Control and Prevention
1600 Clifton Rd
Atlanta, GA 30333 - 800-CDC-INFO
(800-232-4636)
TTY: (888) 232-6348 - New Hours of Operation
8am-8pm ET/Monday-Friday
Closed Holidays - cdcinfo@cdc.gov